AKRO Akero Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: AKRO
Price (delayed)
$53.92
Market cap
$4.31B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.8
Enterprise value
$4.13B
Relative Growth:
Rel. Growth:
5
Relative Strength:
Rel. Strength:
73
Relative Valuation:
Rel. Valuation:
N/A
Relative Profitability:
Rel. Profitability:
6
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein,
Highlights
AKRO's equity is up by 29% year-on-year but it is down by 5% since the previous quarter
Akero Therapeutics's quick ratio has decreased by 50% YoY and by 24% QoQ
AKRO's net income is down by 39% YoY and by 5% QoQ
Key stats
What are the main financial stats of AKRO
Market
Valuations
Earnings
Shares outstanding
79.99M
Market cap
$4.31B
Enterprise value
$4.13B
Price to earnings (P/E)
N/A
Price to book (P/B)
4.19
Price to sales (P/S)
N/A
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$321.48M
Net income
-$283.96M
EBIT
-$279.19M
EBITDA
-$278.91M
Free cash flow
-$253.42M
Per share
Balance sheet
Liquidity
EPS
-$3.8
EPS diluted
-$3.8
Free cash flow per share
-$3.1
Book value per share
$12.87
Revenue per share
$0
TBVPS
$13.57
Total assets
$1.11B
Total liabilities
$83.33M
Debt
$36.03M
Equity
$1.03B
Working capital
$704.2M
Debt to equity
0.04
Current ratio
12.66
Quick ratio
12.29
Net debt/EBITDA
0.66
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-29.1%
Return on equity
-31.6%
Return on invested capital
-39.8%
Return on capital employed
-26.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AKRO stock price
How has the Akero Therapeutics stock price performed over time
Intraday
-0.24%
1 week
-0.63%
1 month
17.12%
1 year
52.83%
YTD
93.82%
QTD
13.56%
Financial performance
How have Akero Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$321.48M
Net income
-$283.96M
Gross margin
N/A
Net margin
N/A
AKRO's net income is down by 39% YoY and by 5% QoQ
Akero Therapeutics's operating income has decreased by 37% YoY and by 4.9% from the previous quarter
Price vs fundamentals
How does AKRO's price correlate with its fundamentals
Growth
What is Akero Therapeutics's growth rate over time
Valuation
What is Akero Therapeutics stock price valuation
P/E
N/A
P/B
4.19
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Akero Therapeutics's EPS has decreased by 10% YoY
The stock's P/B is 35% above its last 4 quarters average of 3.1 and 14% above its 5-year quarterly average of 3.7
AKRO's equity is up by 29% year-on-year but it is down by 5% since the previous quarter
Efficiency
How efficient is Akero Therapeutics business performance
Akero Therapeutics's return on invested capital has increased by 22% YoY and by 6% QoQ
The ROA has contracted by 7% YoY
Akero Therapeutics's return on equity has decreased by 7% YoY
Dividends
What is AKRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AKRO.
Financial health
How did Akero Therapeutics financials performed over time
Akero Therapeutics's quick ratio has decreased by 50% YoY and by 24% QoQ
The current ratio is down by 49% year-on-year and by 25% since the previous quarter
AKRO's debt is 96% smaller than its equity
The debt to equity has grown by 33% from the previous quarter
AKRO's equity is up by 29% year-on-year but it is down by 5% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.